Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShort-Term Debt repayments
Ratios

Kiora Pharmaceuticals (KPRX) Receivables Refunds (2016 - 2025)

Kiora Pharmaceuticals' Receivables Refunds history spans 11 years, with the latest figure at $696002.0 for Q2 2025.

  • For Q2 2025, Receivables Refunds fell 70.15% year-over-year to $696002.0; the TTM value through Jun 2025 reached $696002.0, down 70.15%, while the annual FY2024 figure was $270246.0, 86.82% down from the prior year.
  • Receivables Refunds reached $696002.0 in Q2 2025 per KPRX's latest filing, down from $722290.0 in the prior quarter.
  • In the past five years, Receivables Refunds ranged from a high of $2.3 million in Q2 2024 to a low of $147104.0 in Q1 2021.
  • Average Receivables Refunds over 5 years is $951200.8, with a median of $696002.0 recorded in 2025.
  • Peak YoY movement for Receivables Refunds: surged 20357.99% in 2021, then tumbled 86.82% in 2024.
  • A 5-year view of Receivables Refunds shows it stood at $529560.0 in 2021, then soared by 195.07% to $1.6 million in 2022, then skyrocketed by 31.19% to $2.0 million in 2023, then tumbled by 86.82% to $270246.0 in 2024, then skyrocketed by 157.54% to $696002.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Receivables Refunds are $696002.0 (Q2 2025), $722290.0 (Q1 2025), and $270246.0 (Q4 2024).